The Maryland-based biopharma joins Eli Lilly and Novo Nordisk in trialing a GLP-1 agonist for alcohol- and liver-related ...

As the potential of GLP-1 agonists for addiction gains traction, big pharma is also starting to take notice, namely the two ...

As it gets harder to offer compounded GLP-1s, many telehealth companies are pivoting to hormone replacement therapy.

If you’ve been paying attention to the weight loss world, you’ve probably heard about GLP-1 receptor agonists like Ozempic, ...

Vivani Medical completed enrollment in its LIBERATE-1 trial, testing a six-month GLP-1 implant for weight management.

Despite comments made by a Novo Nordisk official this week, the company confirmed to BioSpace that it has no additional ...

Researchers found that GLP-1 receptor agonists (GLP-1RAs) significantly reduce the risk of several blood cancers in type 2 ...

Biolexis Therapeutics has achieved a transformative milestone in metabolic drug discovery with the successful resolution of ...

Scientists have discovered a naturally-occurring molecule that aids appetite control and weight loss so well, it may compete ...

We know that weight loss drugs have been big winners for the companies that produce them. And now, biotech stock Amgen (AMGN) ...

Less than a year after CordenPharma earmarked a major chunk of change to beef up in peptide manufacturing for GLP-1s and ...

The company will add additional sales for the diagnostic testing business providing a shift in the business and hopefully a focus away from the GLP-1s. Hims has already predicted the launch of ...